FILTER BY:
Details
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Address: 1515 Holcombe Blvd, Houston, TX 77030, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: True
- Peritoneal: True
- Pericardial: True
- Tunica Vaginalis: True
Type: Epitheliod
Condition: Ovarian Cancer, Cholangiocarcinoma Recurrent, Malignant Mesothelioma
Description: This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Research Center: MD Anderson Cancer Center
Treatment Interventions: BIOLOGICAL: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Potential Impact: High
Clinical Trial Number: NCT05568680
Phase: Phase 1
Status: Recruiting
